Tandem Diabetes Care’s symposium held during the 2022 ISPAD conference in Abu Dhabi (UAE) highlights the pediatric glycemic outcomes of the t:slim X2 insulin pump with Control-IQ technology. Dr. Marc Breton revealed the outcomes of the PEDAP randomized clinical trial in children ages 2-5. Dr. Amelie Poidvin reviewed the sustained glycemic control after 2 years of the school-aged FreeLife Kids cohort. And Dr. Laurel Messer reviewed the results of Control-IQ in the adolescent population.